Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Study of Omalizumab in Cholinergic Urticaria (CUN-OMAL-UCOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02012387
Recruitment Status : Completed
First Posted : December 16, 2013
Last Update Posted : February 12, 2019
Sponsor:
Collaborators:
Hospital Clinic of Barcelona
Hospital Universitari Joan XXIII de Tarragona.
Hospital General Universitario Gregorio Marañon
Complejo Hospitalario de Navarra
Hospital Universitario Central de Asturias
Hospital Clínico Universitario Lozano Blesa
Hospital Vall d'Hebron
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra

Tracking Information
First Submitted Date  ICMJE November 18, 2013
First Posted Date  ICMJE December 16, 2013
Last Update Posted Date February 12, 2019
Actual Study Start Date  ICMJE January 2014
Actual Primary Completion Date September 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 9, 2013)
Negativization of the exercise challenge test [ Time Frame: It will be assessed prior to the study, and subsequently each 4 weeks up to 12 months. ]
a. Our primary endpoint will be the negativization of the exercise challenge test: We will perform the exercise challenge test following the European Guidelines[14] for cholinergic urticaria. According with such guidelines, all centers will follow the same center standardized protocol. The patient will exercise in treadmill or running to the point of sweating and following for 15 more minutes, wearing warm clothing in a warm room. The test will be considered positive if exercise challenge leads to the typical rash over 10 minutes.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2019)
  • Chonic Urticaria Quality of life [ Time Frame: It will be evaluated up to 48 weeks. ]
    Quality of Life: QoL will be evaluated through the Spanish validated version of Chronic Urticaria quality of life (CU-Q2oL)
  • Patients' card [ Time Frame: It will be assessed up to 48 weeks. ]
    Use of medication, VAS, daily symptoms, emergency visits, days off work.
  • Treatment drop offs in each sequence [ Time Frame: Up to 48 weeks. ]
Original Secondary Outcome Measures  ICMJE
 (submitted: December 9, 2013)
  • Quality of life [ Time Frame: It will be evaluated up to 48 weeks. ]
    Quality of Life: QoL will be evaluated through the Spanish validated version of Chronic Urticaria quality of life (CU-Q2oL)
  • Patients' card [ Time Frame: It will be assessed up to 48 weeks. ]
    Use of medication, VAS, daily symptoms, emergency visits, days off work.
  • Treatment drop offs in each sequence [ Time Frame: Up to 48 weeks. ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy Study of Omalizumab in Cholinergic Urticaria
Official Title  ICMJE Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial
Brief Summary To demonstrate the efficacy and safety of Omalizumab in a new indication, that is cholinergic urticaria.
Detailed Description

Physical urticarias, such as delayed pressure, cholinergic, dermatographism and cold urticaria, are highly disabling conditions[1]. Cholinergic urticaria occurs due to an active (e.g. exercise) or passive (e.g. hot bath) increase in core body temperature, causing itching and small hives with flare reaction on the trunk and limps that fade away upon cooling of the body[2].

As it is the case of chronic urticaria, physical urticarias have a great impact on patients' quality of life[3, 4]. However, these types of urticarias cause even more alteration on quality of life because of the limitations they cause in daily life activities, sports practicing[5] or work performance.

In spite of the high morbidity of this disease and the impact on quality of life, there is no available treatment. Antihistamines that usually control other types of urticaria could only partially alleviate cholinergic urticaria. There is only one paper[6] that shows efficacy doubling the dose of cetirizine above the recommended dosage on the Summary of Product Characteristics (off-label dosage). The poor response to antihistamine is justified by the minimal role of histamine in its physiopathology and only after employing very high doses[7].

The etiology and pathogenesis of hive formation remains unknown, though it is recognized that mast cells are clearly involved[8]. On the other hand, it seems that desensitization or tolerance could be induced in cholinergic urticaria[9]. Thus as it is the case of drug desensitization, Immunoglobulin E (IgE) receptor must also play a role in the development of this physical urticaria[10].

In the past years, the monoclonal humanized anti-IgE antibody (Omalizumab) was shown to be effective in control cholinergic urticaria[11] not respondent to conventional therapies at maximum or off-label doses. A negative response was also reported for cholinergic urticaria[12].

Our rationale for this approach in this type of urticaria is that Omalizumab exerts an inhibitory action on mast cell activation, as is the case of desensitization.

For that purpose, we will perform a multicenter, randomized, double-blind, placebo-controlled parallel clinical trial. We will include 24 patients including both female and male patients (age 14 years or older), non-respondent to antihistamines.

Efficacy will be evaluated through the negativization of the European Academy of Allergy and Clinical Immunology (EAACI), European Dermatology Forum (EDF) and urticaria network e.V (UNEV) standardized exercise challenge test, Visual Analog Scale (VAS), Chronic Urticaria Quality of Life validated questionnaire[13], patients' card of symptoms and use of rescue medication. Additional measures of efficacy will also be: the number of dropouts in each treatment group; the leave days due of urticaria and Emergency Department visits. Finally, safety will be assessed by means of recording and evaluation of adverse reactions during treatment.

As we previously stated, Omalizumab is not indicated for physical or other types of urticaria. The only indication is for treatment of moderate-to-severe allergic asthma. The hypothesis we are working on is that the monoclonal anti-IgE antibody Omalizumab could be as well effective in controlling physical urticaria symptoms in patients non-respondent to conventional therapy. We hypothesize that Omalizumab is able to revert the basophil or mast cell activation present in those urticaria types.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Cholinergic Urticaria
Intervention  ICMJE
  • Biological: Active
    Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
    Other Names:
    • Biological/Vaccine: Omalizumab
    • Other Names:
    • Xolair
  • Biological: Placebo
    Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
    Other Names:
    • Biological/Vaccine: Placebo
    • Other Names: Saline serum
  • Biological: Open labeled
    Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
    Other Names:
    • Biological: Omalizumab
    • Other Names:
    • Xolair
Study Arms  ICMJE
  • Active Comparator: Active
    Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
    Intervention: Biological: Active
  • Placebo Comparator: Placebo
    Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
    Intervention: Biological: Placebo
  • Active Comparator: Open labeled
    After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
    Intervention: Biological: Open labeled
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 9, 2013)
24
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2017
Actual Primary Completion Date September 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Adult female and male patients (age 14 years or older). Diagnosis of cholinergic urticaria trough clinical history and positive challenge test.

Non-respondent to supra therapeutic doses of antihistamines (defined as 2x the maximal dose included in the drug labeling) Written informed consent.

Exclusion Criteria:

Pruritus related to dermatitis or other skin condition. Any systemic disease that hampers follow up or interpretation of data. Omalizumab treatment within the previous 12 months. Any exclusion criteria included in the drug labeling. Any other conditions that do not allow the accomplishment of the clinical trial requisites, such as the abuse of drugs or alcohol.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 14 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02012387
Other Study ID Numbers  ICMJE CUN-OMAL-UCOL
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Clinica Universidad de Navarra, Universidad de Navarra
Study Sponsor  ICMJE Clinica Universidad de Navarra, Universidad de Navarra
Collaborators  ICMJE
  • Hospital Clinic of Barcelona
  • Hospital Universitari Joan XXIII de Tarragona.
  • Hospital General Universitario Gregorio Marañon
  • Complejo Hospitalario de Navarra
  • Hospital Universitario Central de Asturias
  • Hospital Clínico Universitario Lozano Blesa
  • Hospital Vall d'Hebron
Investigators  ICMJE Not Provided
PRS Account Clinica Universidad de Navarra, Universidad de Navarra
Verification Date April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP